Skip navigation

Does your patient have molecular residual disease? Signatera looks deeper in breast cancer

Personalized tumor-informed test for actionable intelligence in breast cancer

Stay updated on our latest data presentations

Signatera has been used in clinical trials for over 500 Breast Cancer patients and that number is growing. See our two recently announced Breast Cancer studies:

Dare Study

Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera

LEADER Study Part 2

Study to use Signatera to test effectiveness of Ribociclib in combination with endocrine therapy versus standard endocrine therapy

Dive Deeper Into How Signatera Can Improve Your Breast Cancer Clinical Trial

Learn More

Sign up to our clinical trial mailing list.

Reach out to to find out how Signatera can support your clinical trials and Breast Cancer patients.